The Quantellect read.As of Nov 19, 2026, 5 active firms cover DaVita HealthCare Partners Inc: 3 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $215.00 to $270.00, so the covering firms are broadly aligned. The average target of $229.80 sits 42% above the current $161.87. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.30 next quarter toward $16.88 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy360%
Neutral240%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$229.80
+42.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $161.87 current
Highest Target$270.00
Average Target$229.80
Lowest Target$215.00
Detailed analyst forecasts for DVA
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 3 of 5 active firms rate DVA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DVA EPS & revenue forecast
EPS · NEXT QUARTER
$3.30
Range $3.15 – $3.53 · 3 analysts · +15% YoY
Next period, 3 analysts expect DaVita HealthCare Partners Inc to earn $3.30 a share (range $3.15 – $3.53), versus $2.87 a year earlier. Full-year consensus is $14.70, growing to $16.88 the year after.
REVENUE · NEXT QUARTER
$3.5B
Range $3.5B – $3.5B · 3 analysts · +3% YoY
Revenue is expected to reach $3.5B (range $3.5B – $3.5B), +3.2% year-over-year. Full-year consensus is $14.2B, rising to $14.8B next year.
Top analysts covering DaVita HealthCare Partners Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DVA.
#1
DM
David Macdonald
Truist Securities · Rank #111
Neutral
$215.00+32.8% to target
Overall win rate
50%
+ Follow
#2
AR
A.J. Rice
UBS · Rank #365
Buy
$270.00+66.8% to target
Overall win rate
35%
+ Follow
#3
Andrew Mok
Barclays · Rank #385
Neutral
$224.00+38.4% to target
Overall win rate
39%
+ Follow
#4
Ryan Langston
TD Cowen
Buy
$220.00+35.9% to target
Coverage
—
+ Follow
#5
PC
Pito Chickering
Deutsche Bank
Buy
$265.00+63.7% to target
Coverage
—
+ Follow
DVA stock forecast FAQ
What is DVA's average 12-month price target?+
The 5 active firms with a live target average $229.80 for DaVita HealthCare Partners Inc over the next 12 months, ranging from a $270.00 high to a $215.00 low, as of Nov 19, 2026.
Is DVA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DVA?+
The Street-high target is $270.00 (UBS), and the Street-low is $215.00 (Truist Securities). The average of all 5 active-firm targets is $229.80.
How many active Wall Street firms cover DVA?+
5 active firms have a recognized rating on DaVita HealthCare Partners Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DVA?+
Among analysts who currently cover DVA, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #111). Their current call is Neutral with a $215.00 target.
What is DaVita HealthCare Partners Inc's projected EPS for next quarter?+
The consensus estimate is $3.30 per share (range $3.15 – $3.53) across 3 analysts. Full-year EPS is projected at $14.70, rising to $16.88 the following year.
How much revenue is DaVita HealthCare Partners Inc expected to report next quarter?+
Consensus revenue is $3.5B (range $3.5B – $3.5B). Full-year revenue is projected at $14.2B, growing to $14.8B next year.
Have analysts been upgrading or downgrading DVA lately?+
As of Nov 19, 2026, 3 of 5 active firms rate DVA a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.